BufferGel

a topical gel containing CARBOPOL, a highly carboxylated polymer composed of lightly cross-linked polyacrylic acid with a broad-spectrum mechanism based on acidification of pathogens; tradename of ReProtect LLC;

Networked: 10 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mwethera, Peter G: 2 articles (01/2021 - 06/2012)
2.	Obiero, Jael: 2 articles (01/2021 - 06/2012)
3.	HIV Prevention Trials Network (HPTN) 035 Study Team: 2 articles (08/2014 - 04/2011)
4.	Hillier, Sharon L: 2 articles (08/2014 - 04/2011)
5.	Ramjee, Gita: 2 articles (08/2014 - 04/2011)
6.	Ogongo, Paul: 1 article (01/2021)
7.	Wiysonge, Charles S: 1 article (01/2021)
8.	Chilongozi, David: 1 article (08/2014)
9.	Gomez, Kailazarid: 1 article (08/2014)
10.	Guffey, M Bradford: 1 article (08/2014)

Related Diseases

1.	Sexually Transmitted Diseases (Sexually Transmitted Disease) 07/01/2001 - "To test the efficacy of BufferGel for preventing sexually transmitted infections and pregnancy in animal models. " 07/01/2001 - "Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models." 08/01/2014 - "Incidences of STIs were determined by study arm, and HRs of BufferGel and PRO 2000 versus placebo gel or no gel control groups were computed using discrete time Andersen-Gill proportional hazards model. " 08/01/2014 - "Between 2005 and 2007, 3099 women were enrolled in HIV Prevention Trials Network (HPTN) protocol 035, a phase II/IIb evaluation of the safety and effectiveness of BufferGel and PRO 2000 for prevention of STIs, including Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV). " 08/01/2014 - "HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women."
2.	Reproductive Tract Infections 02/01/2004 - "We assessed the efficacy of 7 promising formulated agents--CarraGuard, Ushercell, [poly]sodium 4-styrene sulfonate (T-PSS), PRO 2000, ACIDFORM, cellulose acetate phthalate (CAP), and BufferGel--by use of a mouse model of Neisseria gonorrhoeae genital tract infection. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 09/01/1998 - "The 12th World AIDS Conference exhibited presentations on the safety and efficacy of microbicide products currently in development, including: Pro-2000 (Procept), BufferGel ( ReProtect), Protectaid (Biopharm Laboratories), and C31G (Biosyn). "
4.	HIV Infections (HIV Infection) 04/24/2011 - "BufferGel did not alter the risk of HIV infection. " 08/01/2012 - "Topical products that were ineffective in preventing HIV infection include BufferGel, Carraguard, and PRO 2000. " 04/24/2011 - "Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women." 06/13/2012 - "We found that by the end of 2011, nine microbicide RCTs had either been conducted to term (one BufferGel and 0.5% PRO 2000, one Carraguard and one tenofovir trial) or stopped early due to safety concerns (two cellulose sulphate trials) or insufficient rate of HIV infection and low likelihood of showing a protective effect (one 2% PRO 2000, one tenofovir and two SAVVY trials). "
5.	Bacterial Vaginosis 01/01/2001 - "The prevalence of bacterial vaginosis (BV) fell significantly, from 30% at enrollment to 6% at one week, and 7% at two weeks of BufferGel use. "

Related Drugs and Biologics

1.	PRO 2000 (PRO-2000)
2.	Anti-Infective Agents (Microbicides)
3.	Sodium
4.	Protectaid
5.	C 31G
6.	cellulose sulfate
7.	cellulose acetate phthalate
8.	Cellulose
9.	Tenofovir (Viread)
10.	Dapivirine

Related Therapies and Procedures

1.	Contraception (Birth Control)